$OVID
Ovid Therapeutics Inc.

2019 Q1 Form 10-K Financial Statement

#000156459019006804 Filed on March 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.700M $19.10M $4.300M
YoY Change -6.0% 27.33% 19.44%
% of Gross Profit
Research & Development $9.337M $33.79M $6.700M
YoY Change 10.18% -32.38% 67.5%
% of Gross Profit
Depreciation & Amortization $76.54K $141.7K $0.00
YoY Change 190.21% 76.48% -100.0%
% of Gross Profit
Operating Expenses $14.05M $52.93M $11.05M
YoY Change 4.64% 5.92% 45.58%
Operating Profit -$14.05M -$52.93M
YoY Change 4.64%
Interest Expense $300.0K $1.000M $100.0K
YoY Change 50.0% 400.0%
% of Operating Profit
Other Income/Expense, Net $253.3K $952.1K $88.00K
YoY Change 2.57% 225.93%
Pretax Income -$13.80M -$52.00M -$11.00M
YoY Change 4.55% -19.75% 44.74%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.80M -$51.98M -$10.96M
YoY Change 4.68% -19.79% 44.94%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$455.4K -$2.114M -$445.3K
COMMON SHARES
Basic Shares Outstanding 38.65M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.64M $41.50M $87.10M
YoY Change -19.58% -52.35% 67.82%
Cash & Equivalents $54.60M $35.60M $87.13M
Short-Term Investments $5.041M $5.000M
Other Short-Term Assets $1.900M $2.800M $1.500M
YoY Change 26.67% 86.67% 275.0%
Inventory
Prepaid Expenses
Receivables $1.300M
Other Receivables $0.00
Total Short-Term Assets $62.80M $44.30M $88.59M
YoY Change -17.03% -50.0% 69.03%
LONG-TERM ASSETS
Property, Plant & Equipment $66.16K $100.0K $51.78K
YoY Change -33.84% 0.0% 18.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $331.1K $3.300M $124.2K
YoY Change -88.58% 312.5% -24.87%
Total Long-Term Assets $3.856M $3.300M $869.6K
YoY Change 28.02% 266.67% 41.01%
TOTAL ASSETS
Total Short-Term Assets $62.80M $44.30M $88.59M
Total Long-Term Assets $3.856M $3.300M $869.6K
Total Assets $66.66M $47.60M $89.46M
YoY Change -15.3% -46.82% 68.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.410M $3.800M $2.026M
YoY Change 83.77% 90.0% 136.33%
Accrued Expenses $3.661M $5.100M $3.995M
YoY Change -12.83% 27.5% 38.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.072M $8.800M $6.021M
YoY Change 22.3% 46.67% 61.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.300M
YoY Change
Total Long-Term Liabilities $1.300M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.072M $8.800M $6.021M
Total Long-Term Liabilities $1.300M $0.00 $0.00
Total Liabilities $9.410M $8.800M $6.000M
YoY Change 42.57% 46.67% 62.16%
SHAREHOLDERS EQUITY
Retained Earnings -$166.5M -$100.7M
YoY Change 46.18% 180.47%
Common Stock $223.7M $184.2M
YoY Change 20.28% 1871555.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $57.25M $38.80M $83.44M
YoY Change
Total Liabilities & Shareholders Equity $66.66M $47.60M $89.46M
YoY Change -15.27% -46.82% 68.7%

Cashflow Statement

Concept 2019 Q1 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$13.80M -$51.98M -$10.96M
YoY Change 4.68% -19.79% 44.94%
Depreciation, Depletion And Amortization $76.54K $141.7K $0.00
YoY Change 190.21% 76.48% -100.0%
Cash From Operating Activities -$12.87M -$45.56M -$9.000M
YoY Change -0.46% 44.77% 57.89%
INVESTING ACTIVITIES
Capital Expenditures $4.324K $33.87K $100.0K
YoY Change -42.96% -12.94% -200.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$5.000M
YoY Change -100.0%
Cash From Investing Activities -$8.974K -$5.364M $100.0K
YoY Change -99.98% 11218.8% -200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $30.91M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.99M 286.1K 0.000
YoY Change 40994.71% -99.57%
NET CHANGE
Cash From Operating Activities -12.87M -45.56M -9.000M
Cash From Investing Activities -8.974K -5.364M 100.0K
Cash From Financing Activities 30.99M 286.1K 0.000
Net Change In Cash 18.11M -50.64M -8.900M
YoY Change -131.27% -243.91% 53.45%
FREE CASH FLOW
Cash From Operating Activities -$12.87M -$45.56M -$9.000M
Capital Expenditures $4.324K $33.87K $100.0K
Free Cash Flow -$12.87M -$45.59M -$9.100M
YoY Change -0.49% 44.7% 62.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018Q2 dei Entity Public Float
EntityPublicFloat
90400000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36489618
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87125600
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5011034
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2767495
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1462448
CY2018Q4 us-gaap Assets Current
AssetsCurrent
44268147
CY2017Q4 us-gaap Assets Current
AssetsCurrent
88588048
CY2018Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
2797561
CY2017Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
604646
CY2018Q4 us-gaap Security Deposit
SecurityDeposit
122155
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
88940
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69867
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51775
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
391872
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
124194
CY2018Q4 us-gaap Assets
Assets
47649602
CY2017Q4 us-gaap Assets
Assets
89457603
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3755595
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2025766
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5088862
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3995334
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8844457
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6021100
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38647892
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
111378
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
952073
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152695278
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
38805145
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47649602
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24654114
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24654114
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1829
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.11
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19344355
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.35
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24631011
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1829
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51981439
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64806054
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
49294475
CY2017 ovid Stock Issued During Period Value Initial Public Offering Net Of Underwriting Costs And Commissions
StockIssuedDuringPeriodValueInitialPublicOfferingNetOfUnderwritingCostsAndCommissions
69750000
CY2017 ovid Adjustments To Additional Paid In Capital Reclassification Of Deferred Offering Costs
AdjustmentsToAdditionalPaidInCapitalReclassificationOfDeferredOfferingCosts
-3087481
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-464
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27043
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6397756
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
174762
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7063941
CY2017 ovid Non Cash Research And Development Expense
NonCashResearchAndDevelopmentExpense
25861228
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
7063941
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
6397756
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
141733
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
80310
CY2018 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-4610
CY2018 ovid Accrued Interest And Accretion Of Discounts Short Term Investments
AccruedInterestAndAccretionOfDiscountsShortTermInvestments
-1240
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1305047
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
793258
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
229000
CY2018 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-33215
CY2017 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-36590
CY2018 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
2192915
CY2017 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
604646
CY2018 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1649735
CY2017 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1076349
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1093528
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1118627
CY2017 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-7369
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45558480
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31469909
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
50011623
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
45000000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33871
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38907
CY2018 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
318148
CY2017 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
8480
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5363642
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47387
CY2017 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
69750000
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3073808
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
174762
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
111378
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27043
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
286140
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66703235
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-50635982
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
35185939
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51939661
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(B) <font style="color:#000000;">Use of Estimates</font></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</font></p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(C) Risks and Uncertainties</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its drug candidates, ability to obtain regulatory approval of its drug candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition and untested manufacturing capabilities</font>.</p>
CY2018Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
41500000
CY2018 ovid Description Of Ownership Pattern As Per License And Collaboration Agreement
DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement
Ovid and Takeda are sharing 50/50 in the drug development and throughout the life of this compound
CY2018 ovid Percentage Of Net Expenses Of Development Costs Recorded In Research And Development
PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment
0.50
CY2018 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method.
CY2018 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2018 us-gaap Defined Contribution Plan Plan Name
DefinedContributionPlanPlanName
401(k)-retirement plan
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
210034
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
163942
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
36489618
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
36489618
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
5012863
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1829
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
87125600
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
87125600
CY2018Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
5000000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
0
CY2018Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0
CY2018 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
86164
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7063941
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6397756
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2987729
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
683070
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1538342
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4320
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
50915
CY2018 us-gaap Depreciation
Depreciation
35249
CY2017 us-gaap Depreciation
Depreciation
26917
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
391872
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
124194
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
106484
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
53393
CY2018Q4 ovid Clinical Trials Accrual Current
ClinicalTrialsAccrualCurrent
1352133
CY2017Q4 ovid Clinical Trials Accrual Current
ClinicalTrialsAccrualCurrent
753018
CY2017Q4 ovid Collaboration Agreement Accrual Current
CollaborationAgreementAccrualCurrent
754841
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2779021
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1919120
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
772785
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
321852
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
184923
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
246503
CY2018 us-gaap Common Stock Voting Rights
CommonStockVotingRights
One vote for each share held
CY2018 us-gaap Dividend Payment Restrictions Schedule Description
DividendPaymentRestrictionsScheduleDescription
No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid.
CY2018 us-gaap Dividends
Dividends
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
222949
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4298802
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1733673
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1440578
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15744
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1009253
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2337931
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.46
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.71
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.03
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.26
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.61
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.07
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.65
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.23
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.07
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.16
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.10
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.88
CY2017 ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y2M8D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M25D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y11M1D
CY2018 ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y3M3D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M20D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
837036
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
253969
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8174686
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3865036
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
153485
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
153485
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11808408
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M1D
CY2018 ovid Operating Loss Carryforwards Expiration Period Start
OperatingLossCarryforwardsExpirationPeriodStart
2035
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18748000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18971000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
54032804
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35284858
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37195164
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20880120
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1737870
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
714087
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5333006
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3392111
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
869446
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
633745
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
19949
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
10778
CY2018Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
88353
CY2017Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
53038
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
8828914
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
9622535
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54032804
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35284858
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.1362
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.1177
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0061
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0089
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3602
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2918
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0197
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0056
CY2017 ovid Effective Income Tax Rate Reconciliation Deferred Re Measurement
EffectiveIncomeTaxRateReconciliationDeferredReMeasurement
0.1631
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0004
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0005
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
13430000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
13210000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
13176000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
13116000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
247000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
275000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
214000
CY2018Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
216000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-13183000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-12935000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-12962000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-12900000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13183000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12935000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12962000
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12900000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
34262000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
10288000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
9409000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
11048000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
40000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
51000
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
88000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-34239000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-10248000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-9358000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-10960000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34239000
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10248000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9358000
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10960000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.48
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45

Files In Submission

Name View Source Status
0001564590-19-006804-index-headers.html Edgar Link pending
0001564590-19-006804-index.html Edgar Link pending
0001564590-19-006804.txt Edgar Link pending
0001564590-19-006804-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gcmwsdq1nk5x000001.jpg Edgar Link pending
gcmwsdq1nk5x000002.jpg Edgar Link pending
gcmwsdq1nk5x000003.jpg Edgar Link pending
gcmwsdq1nk5x000004.jpg Edgar Link pending
gcmwsdq1nk5x000005.jpg Edgar Link pending
gcmwsdq1nk5x000006.jpg Edgar Link pending
gcmwsdq1nk5x000007.jpg Edgar Link pending
gcmwsdq1nk5x000008.jpg Edgar Link pending
gcmwsdq1nk5x000009.jpg Edgar Link pending
gcmwsdq1nk5x000010.jpg Edgar Link pending
gcmwsdq1nk5x000011.jpg Edgar Link pending
gcmwsdq1nk5x000012.jpg Edgar Link pending
gcmwsdq1nk5x000013.jpg Edgar Link pending
gcmwsdq1nk5x000014.jpg Edgar Link pending
gcmwsdq1nk5x000015.jpg Edgar Link pending
gcmwsdq1nk5x000016.jpg Edgar Link pending
gcmwsdq1nk5x000017.jpg Edgar Link pending
gcmwsdq1nk5x000018.jpg Edgar Link pending
gcmwsdq1nk5x000019.jpg Edgar Link pending
gcmwsdq1nk5x000020.jpg Edgar Link pending
gcmwsdq1nk5x000021.jpg Edgar Link pending
gcmwsdq1nk5x000022.jpg Edgar Link pending
gcmwsdq1nk5x000023.jpg Edgar Link pending
ovid-10k_20181231.htm Edgar Link pending
ovid-20181231.xml Edgar Link completed
ovid-20181231.xsd Edgar Link pending
ovid-20181231_cal.xml Edgar Link unprocessable
ovid-20181231_def.xml Edgar Link unprocessable
ovid-20181231_lab.xml Edgar Link unprocessable
ovid-20181231_pre.xml Edgar Link unprocessable
ovid-ex231_10.htm Edgar Link pending
ovid-ex311_8.htm Edgar Link pending
ovid-ex312_7.htm Edgar Link pending
ovid-ex321_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending